febit biomed gmbh
Innovative Microarray Technologies
Are you looking for a DNA analysis technology platform that is able to adapt to your changing demands? Stop searching – start working today: Geniom allows you to obtain microarray experimentation results from any sequence information within a single day – fast, efficient and reliable.
Service
miRNA Profiling Service with miRBase 12.0
The miRBase is a continuously updated database for miRNA sequences maintained by the Sanger Institute. febit provides services from sample to bioinformatic report based on the latest miRBase 12.0 content. In total there were 2223 new sequences added.
Webinar
Webinar
“The human genome as an RNA machine”
Abstract: The human genome contains about 20,000 protein-coding genes, surprisingly the same number as those in tiny worms. The basis for our complexity - it seems - lies in the 98% of our genome (the so-called "junk" DNA). Professor Matticks studies indicate that these non-protein-coding RNAs (ncRNAs) form a massive hidden network of regulatory information.
News and Events
- 9/22/08 CHI: Exploring Next Generation Sequencingmore
- 8/14/08febit and TGen Collaborate to Study New DNA Capture Methodfebit and TGen today announced the formation of a collaboration in which TGen will evaluate Next-Generation-Sequencing equipment in conjunction with febit’s proprietary Geniom Microarray Technology....
more - 5/27/08Hybselect: febit Receives US Patent for Microfluidic Extraction MethodUsing this innovative technique, researchers are able to isolate genes or genomic regions of interest from a complex DNA sample prior to sequencing....
more - 4/14/08febit First to Offer miRBase 11.0 Biochipfebit today announced its newest miRNA Biochip based on the new miRBase version 11.0 which has been released by the Wellcome Trust Sanger Institute yesterday....
more - 3/31/08febit forms Scientific Advisory BoardThe SAB members, from top research institutions and companies, will provide expert advice on febit’s research and development activities associated with its portfolio development....
more